Author: Karch, Christopher P; Matyas, Gary R; Burkhard, Peter; Beck, Zoltan
Title: Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine Document date: 2019_1_10
ID: yhh3ydok_4
Snippet: One of the most important regions of the HIV-1 Env protein is the V1V2 loop. IgG antibodies raised against this loop were inversely correlated with the risk of infection in the RV144 clinical trial [29] . Studies indicate that the V1V2 loop of the protein does not assume a unique defined structure [30] . As a result of the high density of glycans on the Env protein, most efforts in subunit vaccine development have used mammalian cells for bio-pro.....
Document: One of the most important regions of the HIV-1 Env protein is the V1V2 loop. IgG antibodies raised against this loop were inversely correlated with the risk of infection in the RV144 clinical trial [29] . Studies indicate that the V1V2 loop of the protein does not assume a unique defined structure [30] . As a result of the high density of glycans on the Env protein, most efforts in subunit vaccine development have used mammalian cells for bio-production. However, similar to the influenza hemagglutinin, a potential HIV-1 V1V2 vaccine candidate could be developed with an antigen that is expressed in E. coli, without glycosylation but with native-like conformation to induce high titers of high affinity antibodies that could prevent the initial infection [31] .
Search related documents:
Co phrase search for related documents- affinity antibody and high affinity antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
- affinity antibody and high titer: 1, 2, 3
- affinity antibody and IgG antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- affinity antibody and mammalian cell: 1
- affinity antibody and subunit vaccine: 1, 2
- clinical trial and Env protein: 1
- clinical trial and high density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- clinical trial and high titer: 1, 2, 3, 4
- clinical trial and IgG antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- clinical trial and initial infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- clinical trial and mammalian cell: 1, 2
- clinical trial and subunit vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- clinical trial and subunit vaccine development: 1, 2
- clinical trial and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- coli express and subunit vaccine: 1
- Env protein and high density: 1, 2
- Env protein and high titer: 1, 2, 3
- Env protein and IgG antibody: 1
- Env protein and mammalian cell: 1
Co phrase search for related documents, hyperlinks ordered by date